Physician profile
Rashda Albibi
NPI 1245278225
$1,311.47
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $405 · 2021: $339.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $282.23 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $170.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.27 | 2019-2021 | |
| Tris Pharma INC | $114.72 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $113.84 | 2021 | |
| Jazz Pharmaceuticals INC. | $113.07 | 2019 | |
| Gilead Sciences, INC. | $93.38 | 2020 | |
| Shire North American Group INC | $57.47 | 2019 | |
| Sanofi Pasteur INC. | $51.04 | 2019-2021 | |
| Emmaus Medical, INC. | $41.44 | 2020 | |
| Pfizer INC. | $36.09 | 2019-2021 | |
| Corium, LLC | $35.05 | 2021 | |
| Sobi, INC | $18.62 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.98 | 2019 | |
| Adlon Therapeutics L.P. | $15.90 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.39 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashda Albibi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.